Administrative Core
行政核心
基本信息
- 批准号:8244094
- 负责人:
- 金额:$ 19.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-21 至 2016-08-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAdenocarcinomaAdministratorAlgorithmsBarrett EsophagusBindingBiopsyBudgetsCase Report FormClinicalClinical ResearchCollectionColorConsent FormsContractsCoumarinsCustomDetectionDevelopmentDysplasiaEarly DiagnosisEndoscopesEsophagusFiberFluoresceinFluorescein-5-isothiocyanateFluorescenceFutureGrantHuman ResourcesImageInstitutionInstitutional Review BoardsInvestigationLabelLightMapsMeasuresMichiganNeoplasmsPathologyPatient RecruitmentsPatientsPeptidesPerformancePharmaceutical PreparationsPharmacology and ToxicologyPhasePilot ProjectsProgress ReportsProtocols documentationResearchResearch Project GrantsResearch SupportResolutionResourcesScanningScheduleScreening for cancerScreening procedureSignal TransductionSiteSystemTeleconferencesTestingTimeTissue ProcurementsTrainingUnited States Food and Drug AdministrationUniversitiesValidationVariantWashingtonWorkalpha benzopyronebasecostdesignfluorescence imaginghuman subjectimprovedin vitro testingin vivoinstrumentphase 1 studyprogramsprototypesurveillance strategyvalidation studiesworking group
项目摘要
Core Summary: The Administration Shared Research Resource (Core A) will support the grants and
regulatory management needs for the three research projects, developmental (pilot) projects, cross-BETRNet projects, and other cross-BETRNet activities. Grant management responsibilities include preparing and implementing the Research Center budgets, allocating sub-contracts to participating institutions, performing financial accounting, and communicating with the NCI program managers. In addition, this Core will prepare the Research Center progress reports, set up the regularly scheduled teleconferences, and support the BETRNet working groups. Furthermore, this Core will fulfill the regulatory management responsibilities, including preparing the human subjects protocols for the clinical studies and tissue procurement protocols for the validation studies. This Core will communicate with the institutional IRB and prepare consent forms, case report forms, and patient recruitment tables for the Phase 1 studies. In addition, this Core will arrange for the pharmacology & toxicology studies on the peptides to be performed, work with MICHR to prepare the Investigation of New Drug applications to the US Food and Drug Administration (FDA). This Core is led by the Director Dr. TD Wang with support from the Research Center grants administrator Ms. Michele Bushaw Weston.
核心摘要:政府共享研究资源(核心A)将支持赠款,
三个研究项目、开发(试点)项目、跨BETRNet项目和其他跨BETRNet活动的监管管理需求。补助金管理职责包括编制和实施研究中心预算,将分包合同分配给参与机构,执行财务会计,以及与NCI项目经理沟通。此外,该核心将准备研究中心的进度报告,建立定期安排的电话会议,并支持BETRNet工作组。此外,该核心将履行监管管理职责,包括为临床研究编写人类受试者方案和为确认研究编写组织采购方案。该核心将与机构IRB沟通,并为I期研究准备知情同意书、病例报告表和患者招募表。此外,该核心将安排对肽进行药理学和毒理学研究,与MICHR合作准备向美国食品药品监督管理局(FDA)提交新药申请的调查。该核心由主任王道明博士领导,并得到研究中心赠款管理员米歇尔·布斯顿韦斯顿女士的支持。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Thomas D Wang其他文献
Thomas D Wang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Thomas D Wang', 18)}}的其他基金
Early detection of colorectal cancer in the traditional and serrated pathways
通过传统途径和锯齿状途径早期发现结直肠癌
- 批准号:
10471944 - 财政年份:2020
- 资助金额:
$ 19.02万 - 项目类别:
Early detection of colorectal cancer in the traditional and serrated pathways
通过传统途径和锯齿状途径早期发现结直肠癌
- 批准号:
10244933 - 财政年份:2020
- 资助金额:
$ 19.02万 - 项目类别:
Early detection of colorectal cancer in the traditional and serrated pathways
通过传统途径和锯齿状途径早期发现结直肠癌
- 批准号:
9974634 - 财政年份:2020
- 资助金额:
$ 19.02万 - 项目类别:
Early Detection of Colorectal Cancer on Near-Infrared Molecular Endoscopy
近红外分子内窥镜早期发现结直肠癌
- 批准号:
9922878 - 财政年份:2016
- 资助金额:
$ 19.02万 - 项目类别:
Early Detection of Colorectal Cancer on Near-Infrared Molecular Endoscopy
近红外分子内窥镜早期发现结直肠癌
- 批准号:
9030043 - 财政年份:2016
- 资助金额:
$ 19.02万 - 项目类别:
Multiplexed Multi-Modal Endoscopic Imaging of Cancer Biomarkers
癌症生物标志物的多重多模态内窥镜成像
- 批准号:
8890458 - 财政年份:2015
- 资助金额:
$ 19.02万 - 项目类别:
Project 2: Peptide imaging agents for early targets in progression from BE to EAC
项目 2:用于从 BE 到 EAC 进展的早期靶点的肽显像剂
- 批准号:
10268346 - 财政年份:2011
- 资助金额:
$ 19.02万 - 项目类别:
Project 2: Peptide imaging agents for early targets in progression from BE to EAC
项目 2:用于从 BE 到 EAC 进展的早期靶点的肽显像剂
- 批准号:
10155439 - 财政年份:2011
- 资助金额:
$ 19.02万 - 项目类别:
相似国自然基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
- 批准号:30840003
- 批准年份:2008
- 资助金额:12.0 万元
- 项目类别:专项基金项目
相似海外基金
Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
- 批准号:
478914 - 财政年份:2023
- 资助金额:
$ 19.02万 - 项目类别:
Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
- 批准号:
23K14913 - 财政年份:2023
- 资助金额:
$ 19.02万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
- 批准号:
23K15035 - 财政年份:2023
- 资助金额:
$ 19.02万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
- 批准号:
10442874 - 财政年份:2023
- 资助金额:
$ 19.02万 - 项目类别:
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
- 批准号:
10657069 - 财政年份:2023
- 资助金额:
$ 19.02万 - 项目类别:
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
- 批准号:
23K08326 - 财政年份:2023
- 资助金额:
$ 19.02万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
- 批准号:
23K14614 - 财政年份:2023
- 资助金额:
$ 19.02万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
- 批准号:
23K15075 - 财政年份:2023
- 资助金额:
$ 19.02万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
- 批准号:
23H02698 - 财政年份:2023
- 资助金额:
$ 19.02万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
- 批准号:
10743611 - 财政年份:2023
- 资助金额:
$ 19.02万 - 项目类别:














{{item.name}}会员




